Co-Occurring Disorder Diagnosis: What You Need to Know

A co-occurring disorder diagnosis means a clinician has identified at least one substance use disorder and at least one independent mental health disorder in the same person, both assessed according to DSM-5-TR criteria. SAMHSA and NIDA use the term interchangeably with “dual diagnosis.” If you suspect this applies to you or someone you care about, three steps matter right now:

• Request a combined screening that covers both substance use and mental health symptoms at the same appointment.
• Write down a symptom timeline: when each symptom started, whether it appeared before or after substance use began, and how symptoms changed during periods of reduced use.
• Ask your provider specifically for a biopsychosocial assessment or a referral to a psychiatrist or licensed clinical psychologist who has experience with both conditions.

Getting those three things in motion before your first clinical appointment puts you ahead of most people who arrive with no documented history, which is the single biggest obstacle to an accurate diagnosis.

Key Takeaways

Integrated treatment that simultaneously addresses both substance use and mental health conditions is the evidence-based standard for co-occurring disorders, supported by SAMHSA, NIDA, and DSM-5-TR diagnostic guidance.

Point	Details
Definition	A co-occurring disorder diagnosis requires at least one SUD and one independent mental disorder, each identified using DSM-5-TR criteria.
Prevalence	SAMHSA’s 2024 NSDUH estimated approximately 21.2 million U.S. adults had both a mental illness and a substance use disorder.
First steps	Request combined screening (AUDIT, DAST, PHQ-9, GAD-7), document your symptom timeline, and ask for a biopsychosocial assessment or psychiatric referral.
U.S. resources	Use findtreatment.gov, call SAMHSA’s helpline at 1-800-662-4357, or text 988 for immediate crisis support and referral guidance.
Connected Recovery	Connected Recovery’s 12-bed residential program in Van Nuys provides integrated dual-diagnosis care with 24/7 medical supervision and structured aftercare planning.

Table of Contents

• What does “co-occurring disorder” actually mean?
• Common co-occurring disorder pairings and what symptoms look like
• Why do co-occurring disorders develop?
• How does the diagnostic process actually work?
• What makes co-occurring disorders hard to diagnose correctly?
• What does a co-occurring disorder diagnosis mean for treatment?
• Where can you find help in the United States?
• How long does assessment take, and what does it cost?
• How Connected Recovery implements diagnosis-to-treatment
• What clinicians wish you knew about this process
• Connected Recovery offers integrated dual-diagnosis care in Los Angeles
• Sources

What does “co-occurring disorder” actually mean?

The phrase “co-occurring disorder” describes the simultaneous presence of a substance use disorder (SUD) and one or more mental health disorders in the same individual. “Dual diagnosis” means exactly the same thing; clinicians use both terms, and neither is a formal DSM-5-TR label. “Comorbidity” is the broader medical term for any two conditions existing together, but in addiction medicine it almost always refers to this specific SUD-plus-mental-health pairing.

The distinction matters because “dual diagnosis” is descriptive, not a single diagnostic entry. A clinician must identify each condition separately, name it precisely, and document its severity before a treatment plan can be built around it.

How common is this in the United States?

SAMHSA’s 2024 National Survey on Drug Use and Health (NSDUH) estimated that approximately 21.2 million U.S. adults had both a mental illness and a substance use disorder. That figure is not a niche clinical curiosity. It means co-occurring conditions are the norm rather than the exception among people seeking addiction treatment, and programs that screen for only one condition routinely miss the other.

21.2 million U.S. adults were estimated to have both a mental illness and a substance use disorder, according to SAMHSA’s 2024 NSDUH data.

Metric	Figure
U.S. adults with co-occurring SUD and mental illness (NSDUH 2024)	~21.2 million
Recommended screening frequency in SUD/mental health settings	At least annually
Conditions required for a dual-diagnosis label	At least one SUD + at least one independent mental disorder

Why does scale matter for care planning? Because a program that treats only the substance use disorder without addressing the underlying mental health condition leaves a major driver of relapse untouched. SAMHSA’s guidance is explicit: treat both conditions concurrently, not one after the other.

Common co-occurring disorder pairings and what symptoms look like

NIDA documents a consistent set of mental disorders that appear alongside substance use disorders at elevated rates: depressive disorders, bipolar I disorder, PTSD, anxiety disorders, ADHD, personality disorders, and schizophrenia-spectrum conditions. The pairings below are among the most frequently seen in clinical settings.

Common disorder pairings:

• Depression + alcohol use disorder. Low mood, fatigue, and anhedonia overlap heavily with the depressant effects of alcohol, making it genuinely hard to tell which came first without a careful timeline.
• PTSD or generalized anxiety + opioid or stimulant use. Hyperarousal, intrusive memories, and panic symptoms often drive people toward substances that blunt or accelerate arousal, depending on the individual’s pattern.
• Bipolar I disorder + alcohol use disorder. Manic episodes can increase impulsive drinking, while alcohol can destabilize mood cycling, creating a feedback loop that worsens both conditions.
• ADHD + stimulant misuse or cannabis use. Untreated ADHD creates chronic dysregulation that some people manage informally with stimulants or cannabis before any formal diagnosis is made.
• Schizophrenia-spectrum disorders + cannabis or tobacco use. Cannabis use is disproportionately common in this population and can precipitate or worsen psychotic episodes.

Symptom clusters clinicians watch for:

Mood symptoms: persistent sadness, irritability, mood swings, grandiosity, or emotional blunting that persists beyond acute intoxication or withdrawal.

Anxiety symptoms: chronic worry, panic attacks, hypervigilance, avoidance behaviors, and sleep disruption that predate or outlast substance use.

Psychotic symptoms: hallucinations, paranoia, or disorganized thinking that appear during abstinence, not only during intoxication.

Impulsivity and executive dysfunction: difficulty sustaining attention, poor decision-making, and risk-taking that show up across multiple life domains, not just around substance use.

Withdrawal and tolerance signs: physical dependence markers (tremors, sweating, nausea on cessation) that confirm a physiological SUD component.

Pro Tip: Keep a symptom diary for two to four weeks before your assessment appointment. Note the time, the symptom, and whether you had used any substance in the preceding 24 hours. That log gives a clinician far more diagnostic traction than memory alone.

To illustrate how these combinations actually present: one person might describe years of panic attacks that began in adolescence, well before any alcohol use, followed by a gradual pattern of drinking to manage pre-event anxiety. Another might report that depressive episodes only emerged after heavy cocaine use began in their mid-twenties, with mood lifting during extended abstinence. A third might have received an ADHD diagnosis in childhood, stopped medication in college, and turned to cannabis to manage focus, with anxiety symptoms developing later. Each of these paths leads to a co-occurring disorder diagnosis, but the treatment plan for each looks quite different.

Why do co-occurring disorders develop?

No single cause explains why substance use disorders and mental health conditions cluster together. Several overlapping risk domains are consistently supported by research.

• Genetic vulnerability. Shared genetic factors increase susceptibility to both SUD and several psychiatric disorders. A family history of depression, bipolar disorder, or alcohol use disorder raises individual risk for all three, not just one.
• Early-life trauma and adverse childhood experiences (ACEs). Trauma is one of the strongest predictors of both PTSD and SUD. Exposure to abuse, neglect, or household dysfunction in childhood alters stress-response systems in ways that persist into adulthood.
• Self-medication pathways. People with untreated anxiety, depression, or PTSD often discover that substances temporarily relieve symptoms. That relief is real in the short term, which is precisely why it becomes a trap: the substance use worsens the underlying condition over time while providing just enough relief to sustain the pattern.
• Social determinants. Housing instability, poverty, social isolation, and lack of access to mental health care all increase both SUD risk and psychiatric vulnerability. These factors also delay diagnosis because people in those circumstances rarely have consistent access to the kind of longitudinal care that catches co-occurring conditions.
• Chronic pain and medical comorbidity. Chronic pain conditions are strongly associated with both depression and opioid use disorder. Medical illness more broadly, including HIV, hepatitis C, and traumatic brain injury, raises psychiatric risk and often involves prescribed medications that carry misuse potential.
• Neurobiological overlap. Substance use alters the same brain circuits, particularly dopamine and serotonin pathways, that are dysregulated in depression, anxiety, and psychosis. This overlap means that prolonged substance use can trigger or worsen psychiatric symptoms even in people with no prior history.

SAMHSA’s TIP 42 guidance and NIDA’s research pages both provide further reading on each of these risk domains for clinicians and informed lay readers.

How does the diagnostic process actually work?

Diagnosis of co-occurring disorders is an ongoing, multi-step assessment that typically includes initial screening, a comprehensive biopsychosocial evaluation, and referral to a psychiatrist or clinical psychologist using DSM-5-TR criteria. There is no single test. Here is the sequence most U.S. clinical programs follow.

Step 1: Initial screening at intake. Clinicians administer validated, brief screening tools to flag possible conditions quickly. The four most commonly used instruments are:

• AUDIT (Alcohol Use Disorders Identification Test): a 10-item questionnaire that screens for hazardous and harmful alcohol use and alcohol dependence.
• DAST (Drug Abuse Screening Test): a parallel tool for non-alcohol drug use, available in 10- and 28-item versions.
• PHQ-9 (Patient Health Questionnaire): a 9-item depression screen that also assesses suicidal ideation; widely used in primary care and behavioral health settings.
• GAD-7 (Generalized Anxiety Disorder scale): a 7-item tool that screens for generalized anxiety and can flag PTSD and panic disorder as well.

SAMHSA’s TIP 42 guidance recommends routine screening for co-occurring disorders in both SUD and mental health settings, with full reassessment at least annually.

Step 2: Comprehensive biopsychosocial assessment. When screening indicates possible comorbidity, the clinician conducts a structured interview covering biological history (medical conditions, medications, family psychiatric history), psychological history (prior diagnoses, trauma, symptom timelines), and social context (housing, relationships, employment, legal history). This assessment connects symptoms to life events and timelines, which is the foundation of accurate diagnosis.

Step 3: Collateral history. Family members, prior treatment records, and medical charts often fill in gaps that a person in active addiction cannot reliably provide. Clinicians specifically look for symptom onset relative to first substance use.

Step 4: Referral to a psychiatrist or clinical psychologist. When the biopsychosocial assessment suggests a co-occurring mental health disorder, a specialist referral is standard. The psychiatrist applies DSM-5-TR criteria to each condition independently and may issue a provisional diagnosis pending an observation period.

Step 5: Observation period and confirmed diagnosis. Many psychiatric symptoms resolve or change significantly after a period of abstinence. Clinicians often treat an initial diagnosis as provisional and revise it based on how symptoms behave once substance effects clear. This period can range from days to several weeks, depending on the substance and the severity of use.

Step 6: Ongoing reassessment. Diagnosis is not a one-time event. As treatment progresses and substance effects resolve, the clinical picture often clarifies. A condition that looked like major depression during active alcohol use may turn out to be a substance-induced mood disorder, or it may persist and confirm an independent diagnosis.

Pro Tip: When you contact an intake team, ask directly: “Do you use the AUDIT, DAST, PHQ-9, or GAD-7 at intake, and do you have a psychiatrist on staff or on referral?” A program that cannot answer both questions clearly may not have the infrastructure for a proper dual-diagnosis workup.

You can find what to expect in a full recovery treatment plan after diagnosis on the Connected Recovery blog.

What makes co-occurring disorders hard to diagnose correctly?

Misdiagnosis and underdiagnoses are genuinely common, and understanding why helps you advocate for a more thorough evaluation.

Substance-induced disorders vs. independent disorders. The DSM-5-TR distinguishes between a mental disorder that exists independently and one that is caused by substance intoxication or withdrawal. Anxiety during cocaine withdrawal, for example, is expected and does not automatically indicate an anxiety disorder. A clinician who assesses only during acute intoxication or withdrawal may miss an independent disorder entirely, or may diagnose one that does not actually exist outside the substance context. Clinicians often require a period of abstinence to make this distinction reliably.

Diagnostic overshadowing. This is the tendency to attribute all symptoms to whichever condition is most visible. In an addiction treatment setting, every symptom may get attributed to the SUD; in a psychiatric setting, the substance use may be minimized. Integrated programs reduce this risk by coordinating mental health and addiction care under the same roof.

Incomplete collateral history. Active addiction often impairs memory and motivation to disclose. Without records from prior providers or input from family members, clinicians are working with a partial picture.

Stigma-driven underreporting. People frequently underreport substance use to mental health providers and underreport psychiatric symptoms to addiction providers, fearing judgment or consequences. This is one of the strongest arguments for integrated settings where both issues are treated without hierarchy.

Snapshot assessments. A single intake interview captures one moment. Symptoms during acute withdrawal from alcohol can look like severe depression or panic disorder. Without longitudinal data, a clinician cannot distinguish a state from a trait.

Clinician strategies that improve accuracy:

• Constructing a detailed symptom timeline that maps each symptom to substance use patterns and periods of abstinence.
• Conducting collateral interviews with family members or reviewing prior treatment records.
• Scheduling repeated assessments across the first weeks of treatment rather than relying on a single intake evaluation.
• Using multi-disciplinary input: addiction counselor, psychiatrist, primary care physician, and case manager each contribute a different lens.
• Applying trauma-informed assessment practices, given that co-occurring disorders are associated with elevated suicide risk and high trauma prevalence.

What does a co-occurring disorder diagnosis mean for treatment?

The treatment implication is straightforward: both conditions need to be treated at the same time, in a coordinated program. Integrated treatment that addresses substance use and mental health conditions simultaneously is associated with better outcomes than sequential care, where one condition is treated first and the other addressed later. SAMHSA and NIDA both recommend the integrated model.

Core treatment components for co-occurring disorders:

• Medication-assisted treatment (MAT): buprenorphine, naltrexone, or methadone for opioid use disorder; naltrexone or acamprosate for alcohol use disorder; combined with psychiatric medications where indicated. Connected Recovery’s MAT program integrates these options within the residential setting.
• Cognitive behavioral therapy (CBT): addresses distorted thinking patterns that sustain both substance use and psychiatric symptoms.
• Trauma-informed care: essential for the large proportion of people with co-occurring PTSD or ACE histories; approaches like EMDR or Seeking Safety are commonly used.
• Motivational interviewing (MI): builds readiness to change and reduces ambivalence, particularly useful early in treatment when engagement is fragile.
• Case management: coordinates medical, psychiatric, housing, and legal needs across providers. Case management services are a core component of sustained recovery.
• Family involvement: psychoeducation and family therapy improve outcomes and reduce the likelihood of enabling patterns.
• Relapse prevention planning: structured identification of triggers, coping strategies, and crisis contacts, built into treatment from the start.

Research consistently shows that mental health treatment supports sobriety by addressing the underlying drivers of substance use rather than only the use itself.

Treatment setting trade-offs:

Setting	Best fit	Key consideration
Residential/inpatient	Moderate-to-severe SUD with active psychiatric symptoms, failed outpatient attempts, or need for medical detox	Highest level of structure and medical supervision; allows observation period for diagnosis clarification
Intensive outpatient (IOP)	Stable housing, lower medical risk, motivated for recovery	Requires strong external support system; less supervision during evenings and weekends
Standard outpatient	Mild-to-moderate symptoms, strong social support	Appropriate for maintenance or step-down after higher-level care
MAT-only clinic	Opioid or alcohol use disorder with stable psychiatric status	Addresses physiological dependence; may not include psychiatric services

Where can you find help in the United States?

NIMH recommends coordinated assessment by providers experienced in both substance use and mental disorders to reduce missed diagnoses and guide effective treatment. These U.S. resources are the most reliable starting points.

Key resources:

• findtreatment.gov: SAMHSA’s treatment locator. Search by zip code, filter for dual-diagnosis or co-occurring disorder services, and verify insurance acceptance before calling.
• 988 Suicide and Crisis Lifeline: call or text 988 for immediate crisis support. Counselors can also help connect callers to local mental health and SUD services.
• SAMHSA National Helpline: 1-800-662-4357, free, confidential, 24/7, available in English and Spanish.
• NIMH and NIDA consumer pages: both offer plain-language overviews of co-occurring conditions, treatment options, and how to find qualified providers.
• VA mental health services: veterans with co-occurring disorders can access integrated care through VA medical centers; the VA has specific dual-diagnosis programs at many facilities.
• Community mental health centers (CMHCs): federally funded centers that offer sliding-scale services and are required to serve anyone regardless of ability to pay.

Questions to ask an intake team before committing:

• Which validated screening tools do you use at intake (AUDIT, DAST, PHQ-9, GAD-7)?
• Do you offer integrated dual-diagnosis services, or do you refer psychiatric care out?
• What level of medical supervision is available, and is there a psychiatrist on staff?
• Do you accept my insurance, and do you handle prior authorization for residential care?
• How do you handle a diagnosis that changes during treatment?

Documentation to have ready:

• Current medication list with dosages and prescribing providers.
• Prior psychiatric diagnoses and the approximate dates they were made.
• Dates of symptom onset for each condition you are aware of.
• Relevant medical records, especially for chronic pain, neurological conditions, or prior hospitalizations.
• Insurance card and a list of prior treatment episodes.

How long does assessment take, and what does it cost?

The timeline from first contact to a confirmed dual-diagnosis varies considerably. Initial screening with AUDIT, DAST, PHQ-9, and GAD-7 typically takes 20–40 minutes and can happen at intake. A comprehensive biopsychosocial assessment usually requires one to three hours, sometimes spread across two appointments. Psychiatric evaluation adds another one to two hours and may involve a waiting period of days to weeks depending on provider availability.

The observation period for provisional diagnoses, where clinicians watch how symptoms evolve during early abstinence, can extend the timeline by two to four weeks in a residential setting. That wait is clinically necessary, not administrative delay.

Insurance and cost considerations:

• Verify that your plan covers both SUD treatment and mental health services under the same benefit. The Mental Health Parity and Addiction Equity Act requires most U.S. insurers to cover mental health and SUD benefits at parity with medical benefits, but coverage specifics vary.
• Ask the provider for the CPT codes they bill for assessment (commonly 90791 for psychiatric diagnostic evaluation and 96130–96131 for psychological testing) so you can verify coverage before the appointment.
• Prior authorization is frequently required for residential care. Ask the intake team whether they handle authorization on your behalf, and confirm the timeline.
• Payment options at most programs include private insurance, private pay, and sliding-scale fees at community-based programs. Some residential programs offer payment plans for private-pay clients.

Appointment preparation checklist:

• Bring your symptom timeline document.
• Bring your medication list and insurance card.
• Bring contact information for any prior providers.
• Bring a trusted family member or friend who can provide collateral history if you consent.
• Ask the intake coordinator what paperwork to complete in advance to speed triage.

A personalized treatment plan built after a thorough assessment will reflect all of this information and give you a clearer picture of what the next 30–90 days look like.

How Connected Recovery implements diagnosis-to-treatment

Connected Recovery’s dual-diagnosis residential program in Van Nuys, Los Angeles, is built around the integrated model that SAMHSA and NIDA recommend. The facility operates at 12 beds, which means the clinical team knows each person’s case in detail rather than managing a rotating census of dozens.

Facility profile:

• 12-bed boutique residential facility with 24/7 medical supervision.
• Medically supervised detox as the first phase, allowing the clinical picture to clarify as substance effects resolve.
• Residential dual-diagnosis program that addresses both SUD and co-occurring mental health disorders simultaneously.
• Psychiatric referral and medication management, including MAT where clinically appropriate.

Services provided through the program:

• Initial screening using validated instruments at intake.
• Comprehensive biopsychosocial assessment to establish symptom timelines and diagnostic priorities.
• Psychiatric evaluation and DSM-5-TR-based diagnosis for each identified condition.
• CBT, trauma-informed therapies, and motivational interviewing delivered by licensed clinicians.
• Case management to coordinate medical, psychiatric, and social needs during and after residential care.
• Structured aftercare planning to support the transition from residential to community-based care.

Who this level of care fits:

This setting is appropriate for adults with moderate-to-severe substance use disorder who also present with active psychiatric symptoms, who have not succeeded in outpatient programs, or who need medical supervision during detox before a stable diagnostic picture can emerge. The small census means the psychiatrist and clinical team can track symptom changes in real time, which is exactly what provisional dual-diagnosis cases require.

What clinicians wish you knew about this process

The most common mistake people make going into a dual-diagnosis assessment is trying to present a clean, simple story. They minimize the substance use because they are ashamed, or they downplay the psychiatric symptoms because they do not want to seem “crazy.” Both instincts are understandable, and both make accurate diagnosis harder.

Honest history is the single most useful thing you can bring to a clinical assessment. Clinicians are not there to judge the timeline; they need it to do their job. The more precisely you can describe when symptoms started, how they changed with substance use, and what happened during any periods of abstinence, the faster the diagnostic picture comes into focus.

Patience with the process matters too. A provisional diagnosis is not a failure; it is the clinician being honest about what they can and cannot know during acute withdrawal or early abstinence. Diagnoses often shift in the first weeks of treatment as the brain stabilizes, and that revision is a sign the assessment is working, not that something went wrong. Re-assessment is built into good integrated care, not bolted on as an afterthought.

Connected Recovery offers integrated dual-diagnosis care in Los Angeles

For adults who need medically supervised detox and residential dual-diagnosis treatment, Connected Recovery provides the level of clinical structure that co-occurring disorders require. The 12-bed facility in Van Nuys means you get 24/7 medical supervision, a psychiatrist-involved assessment process, and a treatment team that tracks your diagnostic picture as it evolves, not a one-size program built for volume.

Residential treatment at Connected Recovery includes the full sequence: intake screening, biopsychosocial assessment, psychiatric evaluation, medically supervised detox, integrated dual-diagnosis therapy, and structured aftercare planning. Most major insurance plans are accepted, and the intake team handles prior authorization. To request an assessment or ask about insurance coverage, contact Connected Recovery directly at Connectedrecoverycenter.

Sources

• Chapter 3—Screening and Assessment of Co-Occurring Disorders - Substance Use Disorder Treatment for People With Co-Occurring Disorders - NCBI Bookshelf
• Co-Occurring Disorders and Health Conditions | SAMHSA
• Co-Occurring Disorders and Health Conditions | National Institute on Drug Abuse (NIDA)
• Finding Help for Co-Occurring Substance Use and Mental Disorders - National Institute of Mental Health (NIMH)

This article provides general health information and is not a substitute for professional medical or psychiatric advice. Confirm current diagnostic and treatment options with a qualified clinician or contact SAMHSA at 1-800-662-4357.

Recommended

• Dual Diagnosis Treatment in Van Nuys, CA | Connected Recovery Inc.
• Case Management Services | Connected Recovery Inc. Van Nuys, CA
• Why Recovery Is a Lifelong Process: What You Need to Know | Connected Recovery Inc.
• The Role of Community in Sustained Recovery | Connected Recovery Inc.